Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril

American Journal of Physiology - Renal Physiology

Volumn 289, Issue 2 58-2, 2005, Pages

  Krämer, Stephanie ^a   Loof, Tanja ^a   Martini, Sebastian ^a   Rückert, Matthias ^a   Wang, Yingrui ^a   Böhler, Torsten ^a   Shimizu, Fuijo ^b   Kawachi, Hiroshi ^b   Neumayer, Hans H ^a   Peters, Harm ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Angiotensin converting enzyme inhibition; Transforming growth factor 1

Indexed keywords

ANTIFIBROTIC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRONECTIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMINOGEN ACTIVATOR INHIBITOR 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT OUTCOME;

EID: 22344451818     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00442.2004     Document Type: Article

References (35)

1. Border WA and Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
2. Border WA and Noble NA. Interactions of TGF-β and angiotensin II in renal fibrosis. Hypertension Suppl 31: 181-188, 1998.
3. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Yu Pierschbacher MD, and Ruoslahti E. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360: 361-364, 1992.
4. Chana RS, Martin J, Rahman EU, and Wheeler DC. Monocyte adhesion to mesangial matrix modulates cytokine and metalloproteinase production. Kidney Int 63: 889-898, 2003.
5. Dubus I, Vendrely B, Christophe I, Labouyrie JP, Delmas Y, Bonnet J, and Combe C. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 62: 857-867, 2002.
6. i-dependent mechanism in vitro. Am J Kidney Dis 37: 820-831, 2001.
7. Floege J and Grone HJ. Glomemlar cells in the progression of human and experimental nephropathies. Adv Nephrol Necker Hosp 27: 15-37, 1997.
8. Fujihara CK, Lourdes Noronha I, Malheiros Antunes GR, de Oliveira IB, and Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11: 283-290, 2000.
9. Glander P, Hambach P, Braun KP, Pritsche L, Waiser J, Mai I, Neumayer HH, and Budde K. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 41: 470-476, 2003.
10. Klahr S, Schreiner G, and Ichikawa I. The progression of renal disease. N Engl J Med 318: 1657-1666, 1988.
11. Mezzano SA, Ruiz Ortega M, and Egido J. Angiotensin II and renal fibrosis. Hypertension 38: 635-638, 2001.
12. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, and Shimizu F. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 55: 877-889, 1999.
13. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
14. Peters H, Border WA, Rückert M, Krämer S, Neumayer HH, and Noble NA. L-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int 63: 1382-1392, 2003.
15. Peters H, Martini S, Wang Y, Shimizu F, Kawachi H, Krämer S, and Neumayer HH. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy1 glomerulosclerosis. Kidney Int 66: 1434-1443, 2004.
16. Peters H, Martini S, Woydt R, Rückert M, Shimizu F, Kawachi H, Liefeldt L, Krämer S, and Neumayer HH. Moderate alcohol intake has no impact on acute and chronic progressive anti-thy1 glomerulonephritis. Am J Physiol Renal Physiol 284: F1105-F1114, 2003.
17. Peters H, Noble NA, and Border WA. Targeting TGF-β overexpression in renal disease: maximizing the anti-fibrotic action of angiotensin II blockade. Kidney Int 54: 1575-1583, 1998.
18. Peters H, Wang Y, Loof T, Martini S, Kron S, Krämer S, and Neumayer HH. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis. Kidney Int 66: 2224-2236, 2004.
19. Pfaffi MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
20. i synthesis in D-glucose primed human proximal tubular cells by IL-1β and TNF α. Kidney Int 50: 1546-1554, 1996.
21. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, and Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10: 1542-1549, 1999.
22. Rennard SI, Berg R, Martin GR, Foidart JM, and Robey PG. Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104: 205-214, 1980.
23. Rodriguez IB, Pons H, Herrera AJ, and Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59: 1626-1640, 2000.
24. Rovin BH and Tan LC. Role of protein kinase pathways in IL-1-induced chemoattractant expression by human mesangial cells. Kidney Int 46: 1059-1068, 1994.
25. Rovin BH, Wilmer WA, Danne M, Dickerson JA, Dixon CL, and Lu L. The mitogen-activated protein kinase p38 is necessary for interleukin 1β-induced monocyte chemoattractant protein 1 expression by human mesangial cells. Cytokine 11: 118-126, 1999.
26. Uciechowski P, Saklatvala J, der Ohe J, Resch K, Szamel M, and Kracht M. Interleukin 1 activates jun N-terminal kinases JNK1 and JNK2 but not extracellular regulated MAP kinase (ERK) in human glomerular mesangial cells. FEBS Lett 394: 273-278, 1996.
27. Vesey DA, Cheung C, Cuttle L, Endre Z, Gobe G, and Johnson DW. Interleukin-1β stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-β-dependent mechanism. J Lab Clin Med 140: 342-350, 2002.
28. Wada Y, Morioka T, Oyanagi-Tanaka Y, Yao J, Suzuki Y, Gejyo F, Arakawa M, and Oite T. Impairment of vascular regeneration precedes progressive glomerulosclerosis in anti-thy 1 glomerulonephritis. Kidney Int 61: 432-443, 2002.
29. Walker NJ. Real-time and quantitative PCR: applications to mechanism-based toxicology. J Biochem Mol Toxicol 15: 121-127, 2001.
30. Wapstra FH, van Goor H, Navis G, de Jong PE, and de Zeeuw D. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci (Colch) 90: 393-401, 1996.
31. Wolf G, Butzmann U, and Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 93: 3-13, 2003.
32. Yang CW, Ahn HJ, Kim WY, Li C, Jung JY, Yoon SA, Kim YS, Cha JH, Kim J, and Bang BK. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation 75: 309-315, 2003.
33. Zatz R, Noronha IL, and Fujihara CK. Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies. Am J Physiol Renal Physiol 283: F1167-F1175, 2002.
34. Ziswiler R, Steinmann NK, Kappeler A, Daniel C, and Marti HP. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 9: 2055-2066, 1998.
35. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De-La-Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, and Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.